Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Why Do So Many Investors Come To RESI? It’s Not Only To Meet Startups

30 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Life Science Nation (LSN) brought the Redefining Early Stage Investments (RESI) conference to life four years ago with the vision of creating a circuit of events focused on bringing together life science entrepreneurs and early-stage investors, from a wide variety of categories, based on mutual fit. One of the most prominent themes we’ve witnessed, after 15 RESI conferences in cities across North America, is the complexity and evolution of the early-stage healthcare ecosystem. The variety of capital sources, strategic partners and other critical stakeholders in the industry has created an environment where investment groups/firms find tremendous value in working together to finance, scale and exit companies.

Investors are primarily drawn to RESI by the large number of top tier startups that attend, but RESI has become much more than a place for investors to find startups and vice versa. While the bulk of the meetings that take place at RESI are between investors and entrepreneurs, RESI also provides a venue for investors to find the newest capital sources, complimentary co-investors and foster relationships with a range of otherwise strategic and exit partners.

We took a look at the partnering meeting data, and discovered that in terms of who meets with whom at RESI conferences, investor-to-investor partnering meetings represent the third largest category, after investor-to-startup meetings and startup-to-service provider meetings. Driven by the unique nature of the early-stage healthcare landscape, LSN’s dedication to bringing in a diverse pool of capital providers makes RESI a must-attend event for all investors and entrepreneurs alike.

We asked some regular attendees their thoughts on RESI’s capacity to help investors connect, and here’s what they said:

“RESI provides a dynamic and fast-paced setting for strategic investors, venture capitalists and entrepreneurs to explore the latest innovations that will disrupt conventional healthcare and redefine the means by which we enable health and wellness in our communities.  As strategic investors, we are particularly interested in RESI to find opportunities to build more patient-centric care models, pilot scalable and efficient delivery models and identify business opportunities to successfully tackle the ‘big’ challenges in healthcare.”
Eric Louie, CMO, Healthbox Global Partners

“I have attended multiple RESIs over the years in SF, NYC and Toronto.  Each has given me a unique perspective on the ecosystem of the area and allowed me to connect with like-minded co-investors and strategic partners.  I will definitely be at the RESI in SF this January.”
Sam Ifergan, President & CEO, iGan Partners

“The RESI conference platform is a highly productive forum for me to engage with both early-stage entrepreneurs and investors. The 30-minute format allows for just enough time to gain a high level understanding of an opportunity or an investors profile. I attend several each year and recommend highly when speaking with both founders and co-investors.”
Sean Kearney, Managing Director, Fosun Group

Qualified investment firms can receive up to two complimentary passes to attend the upcoming RESI conference in San Francisco on January 9, 2018. The previous RESI @ JPM event hit capacity two weeks prior to the date of the conference. Please reach out to research@lifesciencenation.com to request registration for the event and take advantage of the RESI partnering system to secure meetings and get the most out of your Tuesday during JPM week.

 

Happy Thanksgiving and Warm Wishes from LSN

23 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

As we continue our mission of supporting early stage life science companies and investors in connecting and building relationships, LSN would like to give thanks for our supporters, sponsors, clients, RESI attendees, and everyone who has played a part in our network this year. We wish you all success in your partnering, networking and fundraising, and ultimately in bringing new health innovations to market.

It was wonderful to see so many of you at our first RESI NYC event last week, and we look forward to reconnecting in San Francisco in January. In the meantime, we’d like to offer you 10 piping hot mandates from investors all around the world who are looking for early stage startups to connect with. If one of these investors is a potential fit for you, please get in touch.

While you enjoy the spread on your own tables at home, click the mandates below to see what the LSN Investor Platform is serving up:

1. Large VC Firm With $600M Fund Exclusively Dedicated to Early-Stage Therapeutics

2. Family Office Invests Broadly in Biotech Companies with Strong Oncology and Immunotherapy Interests

3. Cross-Border VC Fund Invests Opportunistically in USA and China Life Science Technologies

4. Boston-Based Family Office Invests Up to $20M in Life Science Companies

5. Cancer-Focused Foundation Supports Early-Stage Innovations with Grants and Multiple Fund Vehicles

6. USA-Based Venture Capital Looks Globally For Pre-Clinical and Early Prototype Technologies

7. VC Firm with Capital from Family Offices Invests in Biotech Companies in North America and Europe

8. Corporate VC with Europe Headquarters Seeking Innovative Point-of-Care Diagnostics Companies

9. Large VC Firm Invests $400M Fund in Therapeutics, Devices, and Diagnostics Companies

10. European VC Seeking Medtech and Digital Health Opportunities in Cardiovascular, Neurology, Oncology Indications

RESI NYC 2017 – Program Guide Is Here!

9 Nov

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-new

We are counting down the days to the first RESI NYC event on November 15th, and it’s now time for LSN to present the RESI NYC 2017 Program Guide. This RESI event draws upon both the rising biotech ecosystem in New York and also LSN’s global network of investors and strategic movers in the life science space, and in the Program Guide, you can find speakers, sponsors, and innovators from all over the world. To check out the full RESI NYC 2017 content and lineup, view the Program Guide below.

 

Meet RESI NYC’s Investors & Strategics

9 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wpWhether you’re looking to identify your lead investor, fill out a round of funding or explore strategic partnerships, RESI has a robust pool of groups you should be speaking with. As we approach our first ever RESI conference to be held in New York City, we’re pleased to have everything from government organizations and philanthropic venture groups to leading pharmaceutical companies and venture funds represented, all looking for novel technologies and great entrepreneurs. Have a look at some of the folks you can meet.

RESI New York City: Venture Philanthropy Panel Announcement

2 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Venture philanthropic foundations have deep expertise that is often overlooked. Each foundation has a specific, genuine mission towards a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

New York City is home to a great number of life science foundations. LSN has dedicated the Venture Philanthropy panel to the following five incredible Foundations for the RESI New York City Conference on November 15th. Moderated by John Walter, CEO and President of Alliance for Cancer Gene Therapy, the audience will have an exclusive opportunity to hear from:

  • Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
  • Michael Batten, Director, Strategic Partnerships, Juvenile Diabetes Research Foundation (JDRF) T1D Fund
  • Ken LaMontagne, VP of Research, Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Andres Hurtado-Lorenzo, Director of Translational Research, Crohn’s and Colitis Foundation

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals.

Foundations are a strong reminder not to lose track of the mission in life science.

Register before it’s too late to hear first-hand from this fantastic panel!

Meet The Family Offices that Invest Directly in Biotech, Medtech and Healthcare IT Startups

2 Nov

By Lucy Parkinson, Director of Research, LSN

RESI has always aimed to feature a diverse variety of investors, and every RESI event has included a Family Offices panel discussion.  It’s proved to be a field of continuing interest for entrepreneurs, because life science companies often need the patient capital and deep connections that a family office investor can offer.  Family offices are highly idiosyncratic, and many have a specific investment strategy or area of domain expertise that guides their life science investments; in some cases, they’ve developed scientific expertise in a disease that affects a family member.  With many different motivations and strategies to deploy, these investors are an increasingly significant constituency in the life sciences.

For RESI NYC, we’ve gathered family offices that invest in several different life science verticals.  If you’d like to hear more about what they’re interested in and how they make decisions, you can join us at RESI NYC to hear from our panel moderator, Ron Paliwoda (Founder and President, Paliwoda Group), and the panelists:

  • Chuck Stetson (CEO, Stetson Family Office)
  • Sherry Grisewood (Chief Investment Officer, FoxHill Asset Management)
  • Mark Groner (Vice President, Sopris Capital)
  • Kevin Schimelfenig (Managing Partner and CEO, McGeever LLC)

RESI JPM 2018 Early Bird Registration Is Open

26 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On January 9th, 2018, the Redefining Early Stage Investments (RESI) Conference will join the JPM fray again for our largest event yet in San Francisco.

In the last two RESI JPM conferences, we had to close registrations two weeks early as we’d reached capacity. In RESI JPM 2018, LSN is expecting to bring together 500+ fundraising CEOs and 500+ early stage investors from around the globe and host over 2000 scheduled and ad hoc meetings in one high energy day.

RESI JPM will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. Register early to secure your partnering meetings with investors and strategic partners that are a fit.